HR+/HER2- Breast cancer: The effect of online education on clinician knowledge, competence, and confidence in monitoring, mitigating toxicities, and developing patient-centric plans using a team-based approach.

person Urvi Patel Medscape Oncology, Carrollton, TX info_outline Urvi Patel, Nabil Dorkhom, Victoria Phoenix, Jacob Cohen

Authors person Urvi Patel Medscape Oncology, Carrollton, TX info_outline Urvi Patel, Nabil Dorkhom, Victoria Phoenix, Jacob Cohen Organizations Medscape Oncology, Carrollton, TX, Medscape LLC, New York, NY, Medscape, New York, NY Abstract Disclosures Research Funding Pharmaceutical/Biotech Company Eli Lilly Oncology Background: CDK4/6 inhibitors provide effective treatment options for patients with HR-positive, HER2-negative breast cancer (BC), but adherence and persistence can be challenging. To address this gap, a global educational activity was developed that consisted of a 2-hour live streaming virtual meeting with interactive workshops and a 45-minute online enduring activity. The objective of this study was to assess the educational impact of the online enduring educational activity. Methods: To assess educational impact a repeated-pairs pre-/post-assessment study design using 3 knowledge/competence questions, in which everyone served as their own control. A paired samples t-test assessed mean differences in average number of correct responses pre- to post-assessment, and a McNemar’s test assessed significance of improvement in single questions from pre- to post-assessment. P values < .05 are statistically significant. Confidence was also assessed using a pre/post confidence question. The activity launched on June 4, 2021, and data was collected till March 30, 2022. Results: 80 oncologists from outside the US (OUS) and 69 oncologists from the US who answered all the assessment questions were included in the analysis. Each question assessed a learning objective. All three knowledge/competence learning objectives showed a significant improvement in the OUS oncologist group, and 2 of the 3 showed a significant improvement in the US group. Conclusions: This online enduring activity resulted in a significant improvement of oncologists’ knowledge and competence related to clinical evidence for the use of CDK4/6i, managing adverse events associated with CDK4/6i and monitoring patients on CDK4/6i. Confidence of oncologists in counselling patients on the importance of adherence to CDK 4/6 inhibitor therapy also improved in 29% of OUS oncologists and 33% of US oncologists. However, there is still a need for education in a significant percentage of both OUS and US oncologists on this topic. OUS Oncologists US Oncologists Learning Objectives Absolute percent increase in correct responses/confidence after education P value Absolute percent increase in correct responses/confidence after education P value Knowledge regarding the clinical evidence for CDK4/6 inhibitors in the treatment of HR+/HER2- breast cancer 7% < .05 6% < .05 Competence in managing adverse events of CDK4/6 inhibitors in patients with HR+/HER2- breast cancer 13% < .05 3% NS Competence in monitoring plans for patients with HR+/HER2- breast cancer receiving CDK4/6 inhibitors 23% < .05 7% < .05